Specific Activities of Dolastatin 10 and Peptide Derivatives against Cryptococcus neoformans

The biosynthetic peptide dolastatin 10 is currently in phase I and II cancer clinical trials. We evaluated the antifungal spectrum of dolastatin 10 and four structural modifications. In broth macrodilution assays, the peptides were fungicidal for American Type Culture Collection strains and clinical...

Descripció completa

Dades bibliogràfiques

Publicat a:	Antimicrob Agents Chemother
Autors principals:	Pettit, Robin K., Pettit, George R., Hazen, Kevin C.
Format:	Artigo
Idioma:	Inglês
Publicat:	American Society for Microbiology (ASM) 1998
Matèries:	Susceptibility
Accés en línia:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC105973/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9797233/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.42.11.2961
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!